ABBV
Abbvie·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 2
Consensus Rating "Buy"
High Gross Profit Margin
Significant Net Income Decline
High Cash/net Profit Ratio
Revenue Beats Expectation
Bullish Abandoned Baby
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ABBV
Abbvie Inc.
A global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, hematologic oncology, neuroscience, aesthetics and eye care
1 North Waukegan Road, North Chicago, Illinois 60064-6400
Global, diversified research-based biopharmaceuticals
Abbvie Inc. was incorporated in Delaware on April 10, 2012, and holds Abbott's former research-based pharmaceutical business. The company is a global, research-based biopharmaceutical company. Abbvie develops and markets advanced therapies that address some of the world's most complex and serious diseases. Abbvie's products focus on the treatment of chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, Crohn's disease; low testosterone; HIV; endometriosis; thyroid disease; Parkinson's disease; and health conditions such as complications associated with chronic kidney disease and cystic fibrosis. Abbvie's promising new drug pipeline includes more than 20 compounds or indications in Phase II or Phase III development, covering important medical specialties such as immunology, virology, oncology, nephrology, neurological diseases and women's health.
Earnings Call
Q1/2025
Estimate EPS2.4
Actual EPS2.46
Estimate Revenue12.92B
Actual Revenue13.34B
AbbVie's Q1 2025: Key Contradictions in Skyrizi, Rinvoq Pricing, and Humira Dynamics
May 16,2025 02:46
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS2.91
Actual EPS2.97
Estimate Revenue15.03B
Actual Revenue15.42B
AbbVie's Q2 2025 Earnings Call: Unpacking Contradictions in Skyrizi Growth, Inventory Strategies, and Market Dynamics
Aug 02,2025 08:31
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS1.78
Actual EPS1.86
Estimate Revenue15.59B
Actual Revenue15.78B
AbbVie's Q3 2025 Earnings Call: Contradictions in Aesthetics Strategy, Drug Sales, Tariff Mitigation, and Medicare Redesign Impact
Oct 31,2025 03:37
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ABBV has released its 2025 Q3 earnings. EPS was reported at 1.86, versus the expected 1.78, beating expectations. The chart below visualizes how ABBV has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ABBV has released its 2025 Q3 earnings report, with revenue of 15.78B, reflecting a YoY change of 9.10%, and net profit of 188.00M, showing a YoY change of -87.98%. The Sankey diagram below clearly presents ABBV's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
